<DOC>
	<DOC>NCT00194116</DOC>
	<brief_summary>Double-Blind, Placebo-Controlled Divalproex Sodium ER in Bipolar I or Bipolar II Depression Previously Diagnosed and Treated as Recurrent Major Depression: This study recruits males and females aged 18 - 70 who currently meet diagnostic criteria for bipolar I or bipolar II disorder and are currently experiencing an episode of major depression. Patients are randomized to double-blind treatment with divalproex sodium ER or placebo and remain in the study for up to six weeks. This six-week double-blind treatment period is followed by an open-label treatment period of six months duration. This study is sponsored by Abbott Laboratories.</brief_summary>
	<brief_title>Double-blind, Placebo-Controlled Divalproex Sodium ER in Bipolar I or Bipolar II Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>Subject must give consent to participate in the study and sign and date the IRB approved written informed consent form prior to the initiation of any study procedures Subject must be between the ages of 18 and 70 Subject must have a diagnosis of bipolar I or II. Subject must be currently depressed as confirmed by the MiniInternational Neuropsychiatric Interview (MINI) Subject must have a baseline MontgomeryAsberg Depression Scale (MADRS) score of &gt;19 and Young Mania Rating Scale (YMRS) score of &lt;12 Women of childbearing potential must be nonpregnant/nonlactating and using adequate contraception if sexually active Subject must not be using any concomitant psychotropic medications during the acute phase except prn benzodiazepines Subjects lacks the capacity to provide informed consent Subject has currently or previously used divalproex or DvpxER Subject is a serious suicide risk or has medically unstable conditions as judged by the investigators Subject has any alcohol, cocaine, or cannabis dependence within 3 months of study entry Subject has any cocaine, hallucinogens, opiates, crystal methamphetamine, or MMDA abuse within 3 months of study entry</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>